menu
    • menu
    [{"orgOrder":0,"company":"Roswell Park Cancer Institute","sponsor":"TetraLogic Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I","graph3":"Roswell Park Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Roswell Park Cancer Institute \/ TetraLogic Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Roswell Park Cancer Institute \/ TetraLogic Pharmaceuticals"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Birinapant","moa":"||cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ IGM Biosciences"},{"orgOrder":0,"company":"Medivir","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Birinapant","moa":"||cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Infusion","sponsorNew":"Medivir \/ IGM Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ IGM Biosciences"},{"orgOrder":0,"company":"Medivir","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Medivir","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medivir \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Medivir \/ Merck & Co"},{"orgOrder":0,"company":"Jonsson Comprehensive Cancer Center","sponsor":"California Institute for Regenerative Medicine (CIRM) | TetraLogic Pharmaceuticals | Alpha Stem Cell Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jonsson Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jonsson Comprehensive Cancer Center \/ California Institute for Regenerative Medicine (CIRM) | TetraLogic Pharmaceuticals | Alpha Stem Cell Clinic","highestDevelopmentStatusID":"7","companyTruncated":"Jonsson Comprehensive Cancer Center \/ California Institute for Regenerative Medicine (CIRM) | TetraLogic Pharmaceuticals | Alpha Stem Cell Clinic"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TetraLogic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"TetraLogic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TetraLogic Pharmaceuticals \/ Medivir","highestDevelopmentStatusID":"7","companyTruncated":"TetraLogic Pharmaceuticals \/ Medivir"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TetraLogic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TetraLogic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase II","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TetraLogic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TetraLogic Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"TetraLogic Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Birinapant","moa":"cIAP1\/cIAP2","graph1":"Oncology","graph2":"Phase I","graph3":"TetraLogic Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TetraLogic Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"TetraLogic Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Birinapant

    Menu

    Birinapant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medivir

                            Sweden arrow
                            Cosmoprof India
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant,IGM-8444

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : IGM Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Birinapant Clinical Study Initiated By IGM Biosciences

                            Details : Company initiated its clinical study in solid cancers with birinapant (IGM-9427) in combination with IGM’s DR5 agonist antibody IGM-8444. The purpose of this first clinical trial with the combination will be to explore safety and tolerability.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 04, 2021

                            Lead Product(s) : Birinapant,IGM-8444

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : IGM Biosciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medivir

                            Sweden arrow
                            Cosmoprof India
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant,IGM-8444

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : IGM Biosciences

                            Deal Size : $352.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

                            Details : IGM will receive global, exclusive development and commercialization rights for birinapant, a clinical-stage SMAC mimetic that binds to and degrades Inhibitors of Apoptosis Proteins (IAPs), leading to cell death (apoptosis) in tumor cells.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $1.0 million

                            January 11, 2021

                            Lead Product(s) : Birinapant,IGM-8444

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : IGM Biosciences

                            Deal Size : $352.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Cosmoprof India
                            Not Confirmed

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Medivir

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Medivir Strengthens Its Business Development Possibilities Through a Renegotiated Agreement with Tetra Logic R...

                            Details : The original agreement between Medivir and TetraLogic included milestone payments with predetermined amounts as well as royalty obligations to TetraLogic if and when Medivir develops, markets or out-licenses birinapant further.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 11, 2020

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Medivir

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jonsson Comprehensive Cancer Center

                            Country arrow
                            Cosmoprof India
                            Not Confirmed

                            Jonsson Comprehensive Cancer Center

                            Country arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : California Institute for Regenerative Medicine (CIRM) | TetraLogic Pharmaceuticals | Alpha Stem Cell Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or...

                            Details : Birinapant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Fallopian Tube Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 29, 2016

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : California Institute for Regenerative Medicine (CIRM) | TetraLogic Pharmaceuticals | Alpha Stem Cell Clinic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Medivir

                            Sweden arrow
                            Cosmoprof India
                            Not Confirmed

                            Medivir

                            Sweden arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

                            Details : Birinapant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2015

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Cosmoprof India
                            Not Confirmed

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

                            Details : Birinapant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Myelodysplastic Syndromes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 28, 2014

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Cosmoprof India
                            Not Confirmed

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

                            Details : Birinapant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Ovarian Epithelial.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 12, 2013

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Cosmoprof India
                            Not Confirmed

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidi...

                            Details : Birinapant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Myelodysplastic Syndromes.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 10, 2013

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Roswell Park Cancer Institute

                            Country arrow
                            Cosmoprof India
                            Not Confirmed

                            Roswell Park Cancer Institute

                            Country arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : TetraLogic Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

                            Details : TL32711 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 10, 2012

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : TetraLogic Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Cosmoprof India
                            Not Confirmed

                            TetraLogic Pharmaceuticals

                            Country arrow
                            Cosmoprof India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or M...

                            Details : Birinapant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 25, 2010

                            Lead Product(s) : Birinapant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth